Einzeltreffer — DigiBib

Study Objective: To evaluate the efficacy and safety of a new combination product, enalapril-diltiazem ER, when administered over the long term.

Design: Open-label, titration to response, with treatment lasting 46 weeks after a 6-week, double-blind phase.

Setting: Medical clinics in the private and academic sectors.

Patients: Of 265 patients (68% men, 83% Caucasian, mean age 54.9 yrs) with essential hypertension (sitting diastolic blood pressure 95-115 mm Hg) enrolled, 167 completed the trial.

Interventions: Patients received either the dosage of enalapril-diltiazem ER that they were given during the double-blind phase, or were prescribed enalapril 5 mg-diltiazem ER 120 mg once/day. The dosage was increased until blood pressure was controlled or to a maximum of enalapril 10-diltiazem ER 360 mg/day.

Measurements and Main Results: Combination therapy decreased sitting blood pressures by -11.1/-10.6 mm Hg. Overall, 58% of the patients achieved a sitting diastolic blood pressure of 90 mm Hg or below at the end of the study. There was no evidence of tolerance to the agents' antihypertensive effects. The most common drug-related adverse events were cough, headache, dizziness, and asthenia or fatigue.

Conclusion: The combination effectively managed essential hypertension when administered on a long-term basis and was generally well tolerated. It should improve both compliance and management of hypertension.

Titel:	Long-term effectiveness of enalapril plus extended-release diltiazem in essential hypertension.
Autor/in / Beteiligte Person:	Applegate, W ; Cohen, JD ; Wolfson, P ; Davis, A ; Green, S
Zeitschrift:	Pharmacotherapy, Jg. 17 (1997), Heft 1, S. 107-12
Veröffentlichung:	2012- : Malden, MA : Wiley-Blackwell ; <i>Original Publication</i>: [Carlisle, MA : Pharmacotherapy Publications, c1981-, 1997
Medientyp:	academicJournal
ISSN:	0277-0008 (print)
Schlagwort:	Adult Aged Angiotensin-Converting Enzyme Inhibitors administration & dosage Angiotensin-Converting Enzyme Inhibitors adverse effects Calcium Channel Blockers administration & dosage Calcium Channel Blockers adverse effects Delayed-Action Preparations Diltiazem administration & dosage Diltiazem adverse effects Double-Blind Method Drug Therapy, Combination Enalapril administration & dosage Enalapril adverse effects Female Humans Male Middle Aged Treatment Outcome Angiotensin-Converting Enzyme Inhibitors therapeutic use Calcium Channel Blockers therapeutic use Diltiazem therapeutic use Enalapril therapeutic use Hypertension drug therapy
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Language: English [Pharmacotherapy] 1997 Jan-Feb; Vol. 17 (1), pp. 107-12. MeSH Terms: Angiotensin-Converting Enzyme Inhibitors / therapeutic use ; Calcium Channel Blockers / therapeutic use ; Diltiazem / therapeutic use ; Enalapril / therapeutic use ; Hypertension / *drug therapy ; Adult ; Aged ; Angiotensin-Converting Enzyme Inhibitors / administration & dosage ; Angiotensin-Converting Enzyme Inhibitors / adverse effects ; Calcium Channel Blockers / administration & dosage ; Calcium Channel Blockers / adverse effects ; Delayed-Action Preparations ; Diltiazem / administration & dosage ; Diltiazem / adverse effects ; Double-Blind Method ; Drug Therapy, Combination ; Enalapril / administration & dosage ; Enalapril / adverse effects ; Female ; Humans ; Male ; Middle Aged ; Treatment Outcome Substance Nomenclature: 0 (Angiotensin-Converting Enzyme Inhibitors) ; 0 (Calcium Channel Blockers) ; 0 (Delayed-Action Preparations) ; 69PN84IO1A (Enalapril) ; EE92BBP03H (Diltiazem) Entry Date(s): Date Created: 19970101 Date Completed: 19970408 Latest Revision: 20131121 Update Code: 20231215

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Long-term effectiveness of enalapril plus extended-release diltiazem in essential hypertension.